Cellular adaptation to drug exposure: Evolution of the drug-resistant phenotype

Cancer Research

Volumn 57, Issue 22, 1997, Pages 5086-5092

  Matsumoto, Yoshihito ^a   Takano, Hiroshi ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

ADAPTATION; ALLELE; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CELL POPULATION; CROSS RESISTANCE; DRUG EXPOSURE; DRUG RESISTANCE; DRUG TOLERANCE; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; PHENOTYPE; PHOSPHORYLATION; RNA, MESSENGER; SEQUENCE DELETION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0030694313     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. O'Dwyer, P. J., Leyland-Jones, B., Alonso, M. T., Marsoni, S., and Wittes, R. E. Current status of an active anticancer drug. N. Engl. J. Med., 312: 692-700, 1985.
2. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
3. Watt, P. M., and Hickson, I. D. Structure and function of type II DNA topoisomerases. Biochem. J., 303: 681-695, 1994.
4. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature (Lond.), 379: 225-232, 1996.
5. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA., 91: 1781-1785, 1994.
6. Drlica, K., and Franco, R. J. Inhibitors of DNA topoisomerases. Biochemistry, 27: 2253-2259, 1988.
7. Beck, W. T. The cell biology of multiple drug resistance. Biochem. Pharmacol., 36: 2879-2887, 1987.
8. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., and Pastan, I. Expression of a multidrug resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA, 84: 265-269, 1987.
9. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1993.
10. Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., and Wilson, G. M. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54: 5902-5910, 1994.
11. Lorico, A., Rappa, G., Srimatkandada, S., Catapano, C. V., Fernandes, D. J., Germino, J. F., and Sartorelli, A. C. Increased rate of adenosine triphosphatedependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Res., 55: 4352-4360, 1995.
12. Grant, C. E., Vadimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361, 1994.
13. Kaufmann, S. H., Karp, J. E., Jones, R. J., Miller, C. B., Schneider, E., Zwelling, L. A., Cowan, K., Wendel, K., and Burke, P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood, 83: 517-530, 1994.
14. Takano, H., Kohno, K., Ono, M., Uchida, Y., and Kuwano, M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res., 51: 3951-3957, 1991.
15. Glisson, B., Gupta, R., and Hodges, P. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence of a common intracellular target. Cancer Res., 46: 1939-1942, 1986.
16. Ferguson, P. J., Fisher, M. H., Stephenson, J., Li, D., Zhou, B., and Cheng, Y. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res., 48: 5956-5964, 1988.
17. Spiridonidis, C. A., Chatterjee, S., Petzold, S. J., and Berger, N. A. Topoisomerase II-dependent and -independent Mechanisms of etoposide resistant in Chinese hamster cell lines. Cancer Res., 49: 644-650, 1989.
18. Fernandes, D. J., Danks, M. K., and Beck, W. T. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry, 29: 4235-4241, 1990.
19. Cardenas, M. E., Dang, Q., Glover, C. V. C., and Gasser, S. M. Casein kinase II phosphorylates the eukaryote-specific C-Terminal domain of topoisomerase II in vitro. EMBO J., 11: 1785-1796, 1992.
20. Wells, N. J., Fry, A. M., Guano, F., Norbury, C., and Hickson, I. D. Cell cycle phase-specific phosphorylation of human topoisomerase IIα. J. Biol. Chem., 270: 28357-28363, 1995.
21. 1-S phases of the cell cycle. J. Biol. Chem., 269: 6986-6991, 1994.
22. 11 protein kinase C. Mol. Pharmacol., 48: 798-805, 1995.
23. Alghisi, G. C., Roberts, E., Cardenas, M. E., and Gasser, S. M. The regulation of DNA topoisomerase II by casein kinase II. Cell. Mol. Biol. Res., 40: 563-571, 1994.
24. Caron, P. R., Watt, P., and Wang, J. C. The C-terminal domain of Sccharomyces cerevisiae DNA topoisomerase II. Mol. Cell. Biol., 14: 3197-3207, 1994.
25. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicty assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
26. Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., and Green, M. R. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res., 72: 7035-7056, 1984.
27. Winter, E., Yamamoto, F., Almoguera, C., and Perucho, M. A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-ki-ras allele in human tumor cells. Proc. Natl. Acad. Sci. USA, 82: 7575-7579, 1985.
28. Duguet, M., Lavenot, C., Harper, F., Mirambeau, G., and De Recondo, A. M. DNA topoisomerases from rat liver: physiological variations. Nucleic Acids Res., 11: 1059-1075, 1983.
29. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-256, 1976.
30. Hinds, M., Deisseroth, K., Mayes, J., Altschuler, E., Jansen, R., Ledley, F. D., and Zwelling, L. A. Identification of a point in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res., 51: 4729-4731, 1991.
31. Campain, J. A., Gottesman, M. M., and Pastan, I. A novel mutant topoisomerase IIα present in VP-16-resistant human melanoma cell lines has deletion of alanine 429. Biochemistry, 33: 11327-11332, 1994.
32. Elsea, S. H., Hsiung, Y., Nitiss, J. L., and Osheroff, N. A yeast type II topoisomerase selected for resistance to quinolones. J. Biol. Chem., 270: 1913-1920, 1995.
33. Chan, V., Ng, S-W., Eder, J. P., and Schnipper, L. E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposideresistant Chinese-hamster ovary cell line. J. Biol. Chem., 268: 2160-2165, 1993.
34. Bugg, B. Y., Danks, M. K., Beck, W. T., and Suttle, D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA, 88: 7654-7658, 1991.
35. Lee, M-S., Wang, J. C., and Beran, M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J. Mol. Biol., 223: 837-843, 1992.
36. Vassetzky, Y. S., Dang, Q., Benedetti, P., and Gasser, S. M. Topoisomerase II forms multimers in vitro: effects of metals, B-glycerophosphate, and phosphorylation of its C-terminal domain. Mol. Cell. Biol., 14: 6962-6974, 1994.
37. Wells, N. J., Addison, C. M., Fry, A. M., Ganapathi, R., and Hickson, I. D. Serine 1524 is a major site of phosphorylation on human topoisomerase IIa protein in vivo and is a substrate for casein kinase II in vitro. J. Biol. Chem., 269: 29746-29751, 1994.
38. Doyle, L. A., Ross, D. D., Ordonez, J. V., Yang, W., Gao, Y., Tong, Y., Belani, C. P., and Gutheil, J. C. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br. J. Cancer, 72: 535-542, 1995.
39. Hasegawa, S., Abe, T., Naito, S., Kotoh, S., Kumazawa, J., Hipfner, D. R., Deeley, R. G., Cole, S. P. C., and Kuwano, M. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br. J. Cancer, 71: 907-913, 1995.
40. Schneider, E., Horion, J. K., Yang, C., Nakagawa, M., and Cowan, K. C. Multidrug resistance-associated protein gene overexpression, and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etopside resistance. Cancer Res., 54: 152-158, 1994.
41. Mirski, S. E. L., Gerlach, J. H., and Cole, S. P. C. Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res., 47: 2594-2598, 1987.
42. Cole, S. P. C., Chanda, E. R., Dicke, F. P., Gerlach, J. H., and Mirski, S. E. L. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence of decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res., 51: 3345-3352, 1991.